Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.
暂无分享,去创建一个
C. Yeh | R. Chien | Chih-Lang Lin | Li-Wei Chen | Yu-De Chu | Yu‐De Chu
[1] S. Ahn,et al. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma , 2020, Journal of gastroenterology and hepatology.
[2] Kwang-Huei Lin,et al. Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression , 2020, Hepatology International.
[3] Kwang-Huei Lin,et al. COX5B-Mediated Bioenergetic Alteration Regulates Tumor Growth and Migration by Modulating AMPK-UHMK1-ERK Cascade in Hepatoma , 2020, Cancers.
[4] C. Yeh,et al. GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers , 2020, International journal of molecular sciences.
[5] Kwang-Huei Lin,et al. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy , 2019, The Pharmacogenomics Journal.
[6] C. Yeh,et al. The Defective Allele of Aldehyde Dehydrogenase 2 Gene is Associated with Favorable Postoperative Prognosis in Hepatocellular Carcinoma , 2019, Journal of Cancer.
[7] Gregory J. Gores,et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.
[8] C. Yeh,et al. Emergence of Oncogenic‐Enhancing Hepatitis B Virus X Gene Mutants in Patients Receiving Suboptimal Entecavir Treatment , 2019, Hepatology.
[9] H. El‐Serag,et al. Epidemiology and Management of Hepatocellular Carcinoma. , 2019, Gastroenterology.
[10] Li-juan Jiang,et al. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. , 2018, Journal of vascular and interventional radiology : JVIR.
[11] M. Abecassis,et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.
[12] C. Yeh,et al. Combinations of single nucleotide polymorphisms WWOX‐rs13338697, GALNT14‐rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma , 2018, Asia-Pacific journal of clinical oncology.
[13] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[14] M. Kudo,et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.
[15] T. Yeh,et al. GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma , 2017, Oncology letters.
[16] Alan D. Lopez,et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.
[17] Shrikanth S. Gadad,et al. GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment , 2016, Nature Communications.
[18] J. Marrero,et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. , 2016, Journal of hepatology.
[19] C. Yeh,et al. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. , 2016, Pharmacogenomics.
[20] M. Kudo,et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[21] B. Sangro,et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Yeh,et al. Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case–control study , 2014, Scandinavian journal of gastroenterology.
[23] Masao Iwata,et al. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models , 2014, Journal of thyroid research.
[24] C. Yeh,et al. Genotyping the GALNT14 gene by joint analysis of two linked single nucleotide polymorphisms using liver tissues for clinical and geographical comparisons , 2014, Oncology letters.
[25] C. Yeh,et al. GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma. , 2014, Molecular and clinical oncology.
[26] C. Yeh,et al. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma , 2014, International journal of cancer.
[27] Massimo Rossi,et al. Alpha‐fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[28] Susanta Roychoudhury,et al. NF-kappaB Mediated Transcriptional Repression of Acid Modifying Hormone Gastrin , 2013, PloS one.
[29] C. Yeh,et al. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. , 2011, Pharmacogenomics.
[30] C. Yeh,et al. Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma , 2011, BMC Cancer.
[31] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[32] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[33] B. Bell,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.
[34] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[35] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[36] J. Kalbfleisch,et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.
[37] F. Su,et al. Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins , 1996, Journal of virology.